{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:03:17Z","timestamp":1794553397220,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The genetic features and treatment strategies of lateralized overgrowth have been elusive. We performed this study to analyze the genetic characteristics and treatment results of propranolol- or alpelisib-treated patients with lateralized overgrowth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifteen patients with lateralized overgrowth were involved. Clinical characteristics and whole-body magnetic resonance imaging (WB-MRI) findings were evaluated. Targeted exome sequencing with a gene panel of affected tissue and peripheral white blood cells was performed. Propranolol was administered and treatment results were evaluated. The PIK3CA inhibitor alpelisib was prescribed via a managed access program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The identified mutations were\n                      <jats:italic>PIK3CA<\/jats:italic>\n                      (n\u2009=\u20097),\n                      <jats:italic>KRAS<\/jats:italic>\n                      (n\u2009=\u20092),\n                      <jats:italic>PTEN<\/jats:italic>\n                      (n\u2009=\u20091),\n                      <jats:italic>MAP2K3<\/jats:italic>\n                      (n\u2009=\u20091),\n                      <jats:italic>GNAQ<\/jats:italic>\n                      (n\u2009=\u20091),\n                      <jats:italic>TBC1D4<\/jats:italic>\n                      (n\u2009=\u20091), and\n                      <jats:italic>TEK<\/jats:italic>\n                      (n\u2009=\u20091). Propranolol was prescribed in 12 patients, and 7 experienced mild improvement of symptoms. Alpelisib was prescribed in two patients with a\n                      <jats:italic>PIK3CA<\/jats:italic>\n                      mutation, and the reduction of proliferated masses after 1\u00a0year of treatment was proved by WB-MRI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeted exome sequencing identified various genetic features of lateralized overgrowth. Propranolol could be applied as an adjuvant therapy for reducing vascular symptoms, but a PIK3CA inhibitor would be the primary therapeutic strategy for PIK3CA-related overgrowth syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-022-01362-1","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T19:04:02Z","timestamp":1664478242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical and genetic analyses of patients with lateralized overgrowth"],"prefix":"10.1186","volume":"15","author":[{"given":"Yoon-Myung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunha","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hee","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Sang","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Hyun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Sun","family":"Yum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"issue":"5","key":"1362_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41574-019-0180-z","volume":"15","author":"F Brioude","year":"2019","unstructured":"Brioude F, Toutain A, Giabicani E, Cottereau E, Cormier-Daire V, Netchine I. Overgrowth syndromes\u2014clinical and molecular aspects and tumour risk. Nat Rev Endocrinol. 2019;15(5):299\u2013311.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1362_CR2","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/ajmg.c.31757","volume":"181","author":"DD Burkardt","year":"2019","unstructured":"Burkardt DD, Tatton-Brown K, Dobyns W, Graham JM Jr. Approach to overgrowth syndromes in the genome era. Am J Med Genet C Semin Med Genet. 2019;181(4):483\u201390.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"4","key":"1362_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ajmg.c.31531","volume":"172","author":"KM Keppler-Noreuil","year":"2016","unstructured":"Keppler-Noreuil KM, Parker VE, Darling TN, Martinez-Agosto JA. Somatic overgrowth disorders of the PI3K\/AKT\/mTOR pathway and therapeutic strategies. Am J Med Genet C Semin Med Genet. 2016;172(4):402\u201321.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"7","key":"1362_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1104017","volume":"365","author":"MJ Lindhurst","year":"2011","unstructured":"Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med. 2011;365(7):611\u20139.","journal-title":"N Engl J Med"},{"issue":"7711","key":"1362_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","volume":"558","author":"Q Venot","year":"2018","unstructured":"Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC, Hoguin C, Boccara O, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540\u20136.","journal-title":"Nature"},{"issue":"6","key":"1362_CR6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jpag.2019.07.003","volume":"32","author":"JC L\u00f3pez Guti\u00e9rrez","year":"2019","unstructured":"L\u00f3pez Guti\u00e9rrez JC, Lizarraga R, Delgado C, Mart\u00ednez Urrutia MJ, D\u00edaz M, Miguel M, Triana P. Alpelisib treatment for genital vascular malformation in a patient with congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal\/skeletal anomalies and\/or scoliosis (CLOVES) syndrome. J Pediatr Adolesc Gynecol. 2019;32(6):648\u201350.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"1362_CR7","unstructured":"Managed Access Program (MAP) to Provide Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT04085653. Accessed 22 July 2022"},{"key":"1362_CR8","unstructured":"Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib (EPIK-P1). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04285723. Accessed 22 July 2022"},{"key":"1362_CR9","unstructured":"Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04589650. Accessed 22 July 2022"},{"key":"1362_CR10","unstructured":"FDA approves alpelisib for PIK3CA-related overgrowth spectrum. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-alpelisib-pik3ca-related-overgrowth-spectrum. Assessed 22 July 2022"},{"issue":"11","key":"1362_CR11","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00383-018-4347-9","volume":"34","author":"Z Lin","year":"2018","unstructured":"Lin Z, Wang L, Huang G, Wang W, Lin H. Propranolol inhibits the activity of PI3K, AKT, and HIF-1alpha in infantile hemangiomas. Pediatr Surg Int. 2018;34(11):1233\u20138.","journal-title":"Pediatr Surg Int"},{"issue":"3","key":"1362_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3892\/ijmm.2017.2863","volume":"39","author":"D Li","year":"2017","unstructured":"Li D, Li P, Guo Z, Wang H, Pan W. Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT\/mTOR pathway. Int J Mol Med. 2017;39(3):757\u201363.","journal-title":"Int J Mol Med"},{"issue":"3","key":"1362_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2133.2012.11016.x","volume":"167","author":"ST Tan","year":"2012","unstructured":"Tan ST, Itinteang T, Day DJ, O\u2019Donnell C, Mathy JA, Leadbitter P. Treatment of infantile haemangioma with captopril. Br J Dermatol. 2012;167(3):619\u201324.","journal-title":"Br J Dermatol"},{"key":"1362_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151109","author":"CT Seebauer","year":"2022","unstructured":"Seebauer CT, Graus MS, Huang L, McCann A, Wylie-Sears J, Fontaine F, Karnezis T, Zurakowski D, Staffa SJ, Meunier F, et al. Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI151109.","journal-title":"J Clin Invest"},{"issue":"1","key":"1362_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/09546634.2013.869301","volume":"26","author":"C Pf\u00f6hler","year":"2015","unstructured":"Pf\u00f6hler C, Janssen E, Buecker A, Vogt T, M\u00fcller CS. Successful treatment of a congenital extra-truncal vascular malformation by orally administered propranolol. J Dermatolog Treat. 2015;26(1):59\u201362.","journal-title":"J Dermatolog Treat"},{"key":"1362_CR16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-4545","author":"JK Wu","year":"2016","unstructured":"Wu JK, Hooper ED, Laifer-Narin SL, Simpson LL, Kandel J, Shawber CJ. Initial experience with propranolol treatment of lymphatic anomalies: a case series. Pediatrics. 2016. https:\/\/doi.org\/10.1542\/peds.2015-4545.","journal-title":"Pediatrics"},{"key":"1362_CR17","doi-asserted-by":"publisher","unstructured":"Li H (2013) Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. https:\/\/doi.org\/10.48550\/arXiv.1303.3997. Accessed 1 June 2022","DOI":"10.48550\/arXiv.1303.3997"},{"issue":"9","key":"1362_CR18","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The Genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"key":"1362_CR19","unstructured":"Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Meruish ME. et al. (2007) User\u2019s Manual For The SF36v2 Health Survey. 2nd ed. Lincoln, RI: Quality Metric Incorporated"},{"issue":"5","key":"1362_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"D1","key":"1362_CR21","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941-d947.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"1362_CR22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/gim.2016.220","volume":"19","author":"P Kuentz","year":"2017","unstructured":"Kuentz P, St-Onge J, Duffourd Y, Courcet JB, Carmignac V, Jouan T, Sorlin A, Abasq-Thomas C, Albuisson J, Amiel J, et al. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med. 2017;19(9):989\u201397.","journal-title":"Genet Med"},{"key":"1362_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.87623","author":"G Mirzaa","year":"2016","unstructured":"Mirzaa G, Timms AE, Conti V, Boyle EA, Girisha KM, Martin B, Kircher M, Olds C, Juusola J, Collins S, et al. PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight. 2016. https:\/\/doi.org\/10.1172\/jci.insight.87623.","journal-title":"JCI Insight"},{"issue":"4","key":"1362_CR24","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1172\/JCI98589","volume":"128","author":"L Al-Olabi","year":"2018","unstructured":"Al-Olabi L, Polubothu S, Dowsett K, Andrews KA, Stadnik P, Joseph AP, Knox R, Pittman A, Clark G, Baird W, et al. Mosaic RAS\/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Invest. 2018;128(4):1496\u2013508.","journal-title":"J Clin Invest"},{"issue":"4","key":"1362_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000348327","volume":"4","author":"J Soblet","year":"2013","unstructured":"Soblet J, Limaye N, Uebelhoer M, Boon LM, Vikkula M. Variable somatic TIE2 mutations in half of sporadic venous malformations. Mol Syndromol. 2013;4(4):179\u201383.","journal-title":"Mol Syndromol"},{"issue":"3","key":"1362_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.536","volume":"7","author":"E Lalonde","year":"2019","unstructured":"Lalonde E, Ebrahimzadeh J, Rafferty K, Richards-Yutz J, Grant R, Toorens E, Marie Rosado J, Schindewolf E, Ganguly T, Kalish JM, et al. Molecular diagnosis of somatic overgrowth conditions: a single-center experience. Mol Genet Genomic Med. 2019;7(3): e536.","journal-title":"Mol Genet Genomic Med"},{"issue":"2","key":"1362_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajmg.a.36836","volume":"167a","author":"KM Keppler-Noreuil","year":"2015","unstructured":"Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015;167a(2):287\u201395.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"1362_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.845","volume":"7","author":"M Zollino","year":"2019","unstructured":"Zollino M, Ranieri C, Grossi V, Leoni C, Lattante S, Mazza D, Simone C, Resta N. Germline pathogenic variant in PIK3CA leading to symmetrical overgrowth with marked macrocephaly and mild global developmental delay. Mol Genet Genomic Med. 2019;7(8): e845.","journal-title":"Mol Genet Genomic Med"},{"issue":"1","key":"1362_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.591","volume":"6","author":"S Baldari","year":"2015","unstructured":"Baldari S, Ubertini V, Garufi A, D\u2019Orazi G, Bossi G. Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications. Cell Death Dis. 2015;6(1): e1621.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1362_CR30","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/j.1365-2133.2006.07196.x","volume":"154","author":"A Loffeld","year":"2006","unstructured":"Loffeld A, McLellan NJ, Cole T, Payne SJ, Fricker D, Moss C. Epidermal naevus in proteus syndrome showing loss of heterozygosity for an inherited PTEN mutation. Br J Dermatol. 2006;154(6):1194\u20138.","journal-title":"Br J Dermatol"},{"issue":"21","key":"1362_CR31","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1056\/NEJMoa1213507","volume":"368","author":"MD Shirley","year":"2013","unstructured":"Shirley MD, Tang H, Gallione CJ, Baugher JD, Frelin LP, Cohen B, North PE, Marchuk DA, Comi AM, Pevsner J. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368(21):1971\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"1362_CR32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/jhg.2014.95","volume":"59","author":"M Nakashima","year":"2014","unstructured":"Nakashima M, Miyajima M, Sugano H, Iimura Y, Kato M, Tsurusaki Y, Miyake N, Saitsu H, Arai H, Matsumoto N. The somatic GNAQ mutation c.548G>A (p.R183Q) is consistently found in Sturge-Weber syndrome. J Hum Genet. 2014;59(12):691\u20133.","journal-title":"J Hum Genet"},{"issue":"1","key":"1362_CR33","doi-asserted-by":"publisher","first-page":"77e","DOI":"10.1097\/PRS.0000000000001868","volume":"137","author":"JA Couto","year":"2016","unstructured":"Couto JA, Huang L, Vivero MP, Kamitaki N, Maclellan RA, Mulliken JB, Bischoff J, Warman ML, Greene AK. Endothelial cells from capillary malformations are enriched for somatic GNAQ mutations. Plast Reconstr Surg. 2016;137(1):77e\u201382e.","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"1362_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/ng.272","volume":"41","author":"N Limaye","year":"2009","unstructured":"Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, Eklund L, Boon LM, Vikkula M. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet. 2009;41(1):118\u201324.","journal-title":"Nat Genet"},{"issue":"1","key":"1362_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jid.2016.07.034","volume":"137","author":"J Soblet","year":"2017","unstructured":"Soblet J, Kangas J, N\u00e4tynki M, Mendola A, Helaers R, Uebelhoer M, Kaakinen M, Cordisco M, Dompmartin A, Enjolras O, et al. Blue Rubber Bleb Nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations. J Invest Dermatol. 2017;137(1):207\u201316.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1362_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","volume":"15","author":"M Giannakis","year":"2016","unstructured":"Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15(4):857\u201365.","journal-title":"Cell Rep"},{"issue":"13","key":"1362_CR37","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1080\/15384101.2016.1183853","volume":"15","author":"P Gongpan","year":"2016","unstructured":"Gongpan P, Lu Y, Wang F, Xu Y, Xiong W. AS160 controls eukaryotic cell cycle and proliferation by regulating the CDK inhibitor p21. Cell Cycle. 2016;15(13):1733\u201341.","journal-title":"Cell Cycle"},{"issue":"5","key":"1362_CR38","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2337\/db07-1469","volume":"57","author":"K Bouzakri","year":"2008","unstructured":"Bouzakri K, Ribaux P, Tomas A, Parnaud G, Rickenbach K, Halban PA. Rab GTPase-activating protein AS160 is a major downstream effector of protein kinase B\/Akt signaling in pancreatic beta-cells. Diabetes. 2008;57(5):1195\u2013204.","journal-title":"Diabetes"},{"issue":"4","key":"1362_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4161\/cbt.10.4.12426","volume":"10","author":"XH Jiang","year":"2010","unstructured":"Jiang XH, Sun JW, Xu M, Jiang XF, Liu CF, Lu Y. Frequent hyperphosphorylation of AS160 in breast cancer. Cancer Biol Ther. 2010;10(4):362\u20137.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"1362_CR40","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41436-018-0297-9","volume":"21","author":"VER Parker","year":"2019","unstructured":"Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, Sapp JC, Andrews K, Bardou M, Chen KY, et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genet Med. 2019;21(5):1189\u201398.","journal-title":"Genet Med"},{"key":"1362_CR41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212148","author":"G Morin","year":"2022","unstructured":"Morin G, Degrugillier-Chopinet C, Vincent M, Fraissenon A, Aubert H, Chapelle C, Hoguin C, Dubos F, Catteau B, Petit F, et al. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib. J Exp Med. 2022. https:\/\/doi.org\/10.1084\/jem.20212148.","journal-title":"J Exp Med"},{"issue":"11","key":"1362_CR42","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A. Alpelisib: first global approval. Drugs. 2019;79(11):1249\u201353.","journal-title":"Drugs"},{"issue":"6","key":"1362_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129099","volume":"10","author":"E Contini","year":"2015","unstructured":"Contini E, Paganini I, Sestini R, Candita L, Capone GL, Barbetti L, Falconi S, Frusconi S, Giotti I, Giuliani C, et al. A systematic assessment of accuracy in detecting somatic mosaic variants by deep amplicon sequencing: application to NF2 gene. PLoS ONE. 2015;10(6): e0129099.","journal-title":"PLoS ONE"},{"issue":"3","key":"1362_CR44","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jmoldx.2016.01.002","volume":"18","author":"L Qin","year":"2016","unstructured":"Qin L, Wang J, Tian X, Yu H, Truong C, Mitchell JJ, Wierenga KJ, Craigen WJ, Zhang VW, Wong LC. Detection and quantification of mosaic mutations in disease genes by next-generation sequencing. J Mol Diagn. 2016;18(3):446\u201353.","journal-title":"J Mol Diagn"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-022-01362-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T19:08:35Z","timestamp":1664478515000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-022-01362-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1362"],"URL":"https:\/\/doi.org\/10.1186\/s12920-022-01362-1","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"1 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Asan Medical Center (no. 2020-1628). Written informed consent was obtained from all participants and all methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No personally identifiable data is contained in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no disclosures relevant to the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}